The Pharma Data

JULY 18, 2021

VAXNEUVANCE Elicited Superior Immune Responses for Serotypes 3, 22F and 33F Compared to PCV13, Which Are Major Causes of Disease. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) is expected to meet in October to discuss and make recommendations on the use of VAXNEUVANCE in adults.

Disease 52

Disease Immune Response Vaccine FDA Approval 52

The Pharma Data

JUNE 25, 2021

First-Time Disease-Free Survival Data to be Presented During Plenary Session at the 2021 ASCO Annual Meeting. 41.5), KEYTRUDA demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death by 32% compared to placebo (HR=0.68 [95% CI, 0.53–0.87]; KENILWORTH, N.J.–(BUSINESS

Disease 52

Disease Therapies Treatment Medical Schools 52

The Pharma Data

SEPTEMBER 21, 2020

First-line treatments for patients with ovarian cancer are designed to delay the disease’s progression for as long as possible to help achieve long-term remission. The PAOLA-1 trial showed that the combination of Lynparza with bevacizumab as a maintenance treatment reduced the risk of disease progression or death by 67%.

Research Laboratories 52

Research Laboratories Treatment Trials Laboratories 52

The Pharma Data

JULY 12, 2021

The data were presented during the late-breaking clinical trials session at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). In addition, Merck plans to initiate a clinical program to evaluate molnupiravir for post-exposure prophylaxis in the second half of 2021. “It

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories Hospitals 52

The Pharma Data

SEPTEMBER 28, 2021

10) and who haven’t received prior chemotherapy for metastatic disease. Triple-negative carcinoma grows and spreads faster than other sorts of carcinoma and consequently features a worse prognosis,” said Dr. Vicki Goodman, vice chairman , clinical research, Merck Research Laboratories. Source link: [link].

Research Laboratories 52

Research Laboratories Clinical Research Treatment Disease 52

The Pharma Data

JUNE 1, 2022

Under her leadership, Pfizer advanced into clinical development or approval bacterial vaccine programs directed at the prevention of diseases due to Streptococcus pneumoniae, Group B Streptococcus, Neisseria meningitidis, Staphylococcus aureus, and Clostridium difficile. Dr. Anderson joined Pfizer via Wyeth in 2007.

Vaccine 40

Vaccine Research Doctors Laboratories 40

The Pharma Data

AUGUST 31, 2021

“While the treatment landscape has evolved, an unmet need remains for appropriate patients newly diagnosed with certain types of advanced urothelial carcinoma who are not eligible for platinum-containing chemotherapy,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. “We

FDA Approval 52

FDA Approval Treatment FDA Research Laboratories 52

The Pharma Data

MARCH 8, 2021

“We are very pleased to share our initial Phase 2 infectivity data at this important conference, which remains at the forefront for critical clinical scientific information in infectious diseases,” shared Dr. Wendy Painter, Chief Medical Officer of Ridgeback Biotherapeutics. “At About Molnupiravir. About Ridgeback Biotherapeutics.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

JUNE 2, 2023

Many patients with mCRPC are only able to receive one line of therapy, as the disease can progress quickly. and an investigator in the trial, said, “Preventing or delaying radiographic progression is an important clinical endpoint in assessing cancer treatment and is very important to patients, their caregivers and their families.

FDA Approval 52

FDA Approval FDA Therapies Treatment 52

The Pharma Data

APRIL 28, 2023

Results from the PROpel trial showed a statistically significant and clinically meaningful 34% reduction in the risk of radiographic disease progression or death with Lynparza plus abiraterone with prednisone or prednisolone, versus abiraterone alone in patients with mCRPC (hazard ratio [HR] 0.66; 95% confidence interval [CI] 0.54-0.81;

FDA 40

FDA Trials Research Laboratories Treatment 40

The Pharma Data

MARCH 16, 2021

This collaboration with the Lieber Institute further expands our innovative neuropsychiatric research program, a key focus area at Boehringer Ingelheim, with a first-in-class mechanism that may have the potential to address these symptoms,” said Dr. Hugh Marston, Ph.D., Head of Department CNS Diseases Research at Boehringer Ingelheim. “By

Licensing 52

Licensing Licensing Research Laboratories Pharmaceutical Companies 52

The Pharma Data

JUNE 7, 2023

Rubin, senior vice president, global clinical development, Merck Research Laboratories. “Patients with stage III and IV melanoma can be at high risk of having their cancer recur or metastasize to other sites,” said Dr. Eric H.

Clinical Trials 40

Clinical Trials Therapies Research Laboratories Vaccine 40

The Pharma Data

NOVEMBER 22, 2020

PAH is a chronic, progressive disease caused by the hardening and narrowing of the pulmonary arteries that can cause right heart failure and eventual death. The drug also received Rare Pediatric Disease Designation for these indications. It was granted Priority Review. with LEPR deficiency obesity. Featured Jobs on BioSpace.

FDA 52

FDA Licensing Licensing FDA Approval 52

The Pharma Data

AUGUST 7, 2020

Results included global public and private financing from regenerative medicine and advanced therapy developers, and highlighted a 120 per cent increase over the first half of 2019. The ARM report also showcased robust pipelines of therapies targeting indications in cancers, infectious diseases and inherited disorders. Dr. Francis S.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

The Pharma Data

APRIL 28, 2023

Results from the PROpel trial showed a statistically significant and clinically meaningful 34% reduction in the risk of radiographic disease progression or death with LYNPARZA plus abi/pred (HR=0.66 [95% CI, 0.54-0.81]; We look forward to the outcome of the FDA’s review of the application.” months versus 16.6 months, respectively.

FDA 40

FDA FDA Approval Trials Treatment 40

The Pharma Data

OCTOBER 19, 2020

Pneumococcal disease in adults is on the rise globally, in part driven by disease-causing serotypes not targeted by the currently available pneumococcal conjugate vaccine,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

The Pharma Data

JULY 21, 2021

“This announcement reflects another important regulatory milestone in the development of this medicine,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. Forward-Looking Statement of Merck & Co., Kenilworth, N.J.,

Treatment 52

Treatment Production Hospitals FDA Approval 52

The Pharma Data

DECEMBER 17, 2020

Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs. Prior to Fulcrum, Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinical development group. He spent 27 years at Merck & Co.

Small Molecule 52

Small Molecule Engineering Pharmaceuticals Clinical Development 52

The Pharma Data

JANUARY 20, 2021

We are pleased to offer a meaningful new treatment option for appropriate patients with symptomatic chronic heart failure,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. Forward-Looking Statement of Merck & Co., Kenilworth, N.J.,

FDA Approval 52

FDA Approval FDA Hospitals Treatment 52

The Pharma Data

APRIL 11, 2021

50 kg, respectively), taken twice daily until disease progression or unacceptable toxicity. i Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. 15 to 89 mL/min, estimated by Modification of Diet in Renal Disease [MDRD] equation). Retevmo is an U.S.

Research 52

Research Treatment Therapies Trials 52

The Pharma Data

MARCH 15, 2022

“There remains a significant unmet need for patients diagnosed with advanced prostate cancer, who have a poor prognosis after not responding to initial therapy,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. Source link: [link].

DNA 52

DNA Clinical Trials Trials Therapies 52

The Pharma Data

NOVEMBER 18, 2021

All clinical studies provide important learnings to help us in the fight against HIV, and we are grateful to the patients and investigators for their contributions.”. mg daily (DOR/ISL) in HIV-1 virologically suppressed participants. Source link: [link].

Clinical Trials 52

Clinical Trials Treatment Trials RNA 52

The Pharma Data

AUGUST 30, 2021

“We are pleased to offer two potential new treatment options with KEYTRUDA for patients in Japan based on compelling data from our clinical trial program,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. months (95% CI, 7.6-11.3)

Treatment 52

Treatment Research Laboratories Trials Packaging 52

The Pharma Data

JULY 21, 2021

For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. Forward-Looking Statement of Merck & Co., Kenilworth, N.J.,

Clinical Trials 52

Clinical Trials Pharmacokinetics Trials International 52

The Pharma Data

JULY 15, 2021

0.82]; p=0.00031) versus the chemotherapy-placebo regimen – a statistically significant and clinically meaningful EFS result. EFS was defined as the time from randomization to the first occurrence of either disease progression that precluded definitive surgery, a local/distant recurrence, a second primary cancer, or death from any cause.

Therapies 52

Therapies Treatment Trials FDA 52

The Pharma Data

JULY 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from the company’s HIV clinical development program at the 11th International AIDS Society Conference on HIV Science (IAS 2021) from July 18-21. In patients with chronic kidney disease, also assess serum phosphorus.

Pharmacokinetics 52

Pharmacokinetics Clinical Trials Trials Treatment 52

The Pharma Data

MARCH 8, 2021

“We are delighted to share our early data at CROI 2021 supporting the potential for a once-yearly dosing regimen for islatravir using a subdermal implant,” said Dr. Joan Butterton, vice president, global clinical development, infectious diseases, Merck Research Laboratories. “We Source link:[link].

Trials 52

Trials Clinical Trials Pharmacokinetics Research Laboratories 52

The Pharma Data

APRIL 7, 2023

Gregory Lubiniecki, Vice President, Global Clinical Development, Merck Research Laboratories. Senior Vice President, Clinical Development, Oncology at Eisai Inc. It is estimated there will be nearly 100,000 new cases of melanoma diagnosed and approximately 8,000 deaths resulting from the disease in the U.S.

Trials 40

Trials Clinical Trials Treatment Therapies 40

The Pharma Data

MARCH 5, 2021

In the Phase 2, patients are enrolled across various cohorts, depending on disease type and prior therapy. Loxo Oncology at Lilly was created in December 2019, combining the Lilly Research Laboratories oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019. The primary endpoint for Phase 2 is ORR.

Pharmacokinetics 52

Pharmacokinetics Clinical Trials Trials Therapies 52

The Pharma Data

NOVEMBER 19, 2020

Previously, Baffa was Therapeutic Area Head of Oncology, Global Clinical Development for Shire. Gelbman most recently served as the founding CEO of FDNA, a digital health startup that develops advanced AI tools to help diagnose patients with rare diseases.

Laboratories 52

Laboratories Research Laboratories Organic Chemistry Science 52

The Pharma Data

MARCH 23, 2021

0.86]; p<0.0001) and reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.55-0.76]; We are committed to putting patients first and continuing our research to help advance new approaches to potentially extend the lives of people with cancer. Ninety-one percent had M1 disease, and 9% had M0 disease.

Treatment 52

Treatment FDA Approval FDA Therapies 52

The Pharma Data

AUGUST 10, 2021

The FDA’s acceptance of our application adds to our momentum of advancing new treatment options to address the most challenging cancers facing women,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. In the U.S.,

FDA 52

FDA Therapies Treatment Research Laboratories 52

The Pharma Data

APRIL 4, 2023

Patients were treated until disease progression or unacceptable toxicity. Thirty-seven percent of patients had upper tract disease. Patients in the dose escalation cohort (n=5), Cohort A (n=40), and Cohort K (n=76) received enfortumab vedotin 1.25 A total of 121 patients received KEYTRUDA in combination with enfortumab vedotin.

Treatment 40

Treatment FDA Approval FDA Therapies 40

The Pharma Data

NOVEMBER 22, 2020

Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. Islatravir is a promising antiviral candidate with evidence from ongoing clinical trials to support its development as a once-monthly oral PrEP agent. Kenilworth, N.J.,

Trials 52

Trials Clinical Trials International Production 52